About the journal
Expert Opinion on Emerging Drugs is a journal published by Taylor & Francis in United Kingdom. It is listed in MEDLINE according to the sources read. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Taylor & Francis
- ISSN
- 1472-8214 · 1744-7623
- Country
- United Kingdom
- Access
- Not open access / not declared
- Declared peer-review model
- peer_review
- Official website
- http://informahealthcare.com/journal/emd
Index listings
- MEDLINE · 2003-01-01
- Indexing
- MEDLINE
- APC
- —
- Declared review time (DOAJ)
- —
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
1028
Last recorded publication year
2025
h-index
64
i10-index
586
From OpenAlex open data (CC0).
Editorial & policy5
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 99%
- ORCID iDs in current deposits
- 33%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 101135662
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Asthma and respiratory diseases
- Asthma and respiratory diseases
- Retinal Diseases and Treatments
- Retinal Diseases and Treatments
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
Show all subjects (50)
- CAR-T cell therapy research
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Psoriasis: Treatment and Pathogenesis
- HER2/EGFR in Cancer Research
- Psoriasis: Treatment and Pathogenesis
- Rheumatoid Arthritis Research and Therapies
- Rheumatoid Arthritis Research and Therapies
- Chronic Lymphocytic Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Phosphodiesterase function and regulation
- Pharmacological Receptor Mechanisms and Effects
- Pharmacological Receptor Mechanisms and Effects
- Phosphodiesterase function and regulation
- Diabetes Treatment and Management
- Immunotherapy and Immune Responses
- Acute Myeloid Leukemia Research
- Lipoproteins and Cardiovascular Health
- Diabetes Treatment and Management
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Lipoproteins and Cardiovascular Health
- Chronic Myeloid Leukemia Treatments
- Peptidase Inhibition and Analysis
- Peptidase Inhibition and Analysis
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Dermatology and Skin Diseases
- Dermatology and Skin Diseases
- Sexual function and dysfunction studies
- Gastrointestinal motility and disorders
- Hepatitis C virus research
- Cholinesterase and Neurodegenerative Diseases
- Neurotransmitter Receptor Influence on Behavior
- Hepatitis C virus research
- Gastrointestinal motility and disorders
- Sexual function and dysfunction studies
- Cholinesterase and Neurodegenerative Diseases
- Neurotransmitter Receptor Influence on Behavior
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ